CALL/NOVO-NORDISK B/1500/0.1/19.12.25 | Market Closed - Börse Stuttgart 10:23:35 31/05/2024 BST | ||
| 0.48 EUR | -2.04% |
|
| 1 month | +4.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.48 | -2.04% |
| 30/05/24 | 0.49 | +13.95% |
| 29/05/24 | 0.43 | -10.42% |
| 28/05/24 | 0.48 | -2.04% |
| 27/05/24 | 0.49 | -5.77% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 10:23 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG4UHN |
| ISIN | DE000GG4UHN3 |
| Date issued | 05/03/2024 |
| Strike | 1,500 kr |
| Maturity | 19/12/2025 (567 Days) |
| Parity | 10 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.39 € |
| Spread | 0.05 € |
| Spread % | 9.43% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
